RE:RE:RE:RE:ONCY January 2024 slide deck - over 120 panc pts studiedReportedly the one year survival for Stage IV (advanced or metastatic) cancer patients is 8% which would mean that in ONCY's Phase 2 Goblet-1 pancreatic cancer cohort with 13 evaluable patients, only 1.04 patients should have reached the one year survival milestone.
However in October 2023 ONCY reported that the 12 month survival rate in the evaluated Stage IV patients was 46%, suggesting that 6 patients were still alive, thus surpassing Stage IV pancreatic cancer historical survival rates by 6 fold. Summary of Data and Findings from the PDAC Arm of the Phase 1/2 GOBLET Study:
Tumor Responses: Consistent with the abstract, data from the study outlined patient responses, including:
-- Objective Response Rate (ORR) of 62% (54% confirmed by two or more scans)
-- A Disease Control Rate (DCR) of 85%
Survival data: Evaluated based on 4 parameters including:
-- Median duration of response was 5.7 months
-- Median progression-free survival (PFS) was 7.2 months
-- Interim 12-month survival rate was 46%
-- Interim median overall survival (OS) was 10.6 months
T-Cell Populations: Analysis of changes of T-cell clones and tumor-infiltrating lymphocytes (TILs) showed:
-- Mean baseline TIL cell levels of 22%
-- Expansion of pre-existing and new T cell clones, including the expansion of TIL-specific clones
-- A correlation between the expansion in the blood of TIL-specific clones and tumor response.
https://oncolyticsbiotech.com/press_releases/oncolytics-presents-positive-updated-pancreatic-cancer-data-from-goblet-phase-1-2-study-at-esmo/